Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05005442
Title A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

Hodgkin's lymphoma

non-Hodgkin lymphoma

multiple myeloma

primary mediastinal B-cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

MK-7684A

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.